Addressing one of healthcare’s largest unmet needs with precision biologic therapies that reduce risk, support recovery, and move beyond opioid-dependent treatment models.
The Problem We Are Solving
Millions of U.S. patients experience acute musculoskeletal injuries and undergo orthopaedic procedures each year, making acute pain management one of the largest drivers of healthcare utilization. There is a critical need for safe, tissue-specific alternatives that work with the body’s natural biology, not against it.
Despite advances in care, acute pain treatment still relies heavily on opioids, exposing patients to avoidable safety risks, delayed recovery, and long-term dependency concerns.
Federal policy is now actively supporting non-opioid alternatives: the NOPAIN Act establishes separate Medicare reimbursement for FDA-approved non-opioid pain therapies used in hospital outpatient and ambulatory surgical settings.
This policy shift accelerates adoption and creates a clear commercial pathway for effective, non-opioid biologic solutions addressing acute musculoskeletal pain.
ARCK Biologics is ready to help solve the critical need for safe, tissue-specific alternatives that work with the body’s natural biology, not against it.
Our Mission
To transform acute musculoskeletal pain management through targeted, non-opioid biologic solutions that deliver meaningful, lasting relief, while also aiding faster recovery without systemic exposure or dependency risk.
Our Vision
A future where recovery is faster, clinicians have access to safer, targeted solutions, and acute pain is treated with scientific precision—eliminating the need for dependency-forming medications and minimizing systemic side effects.
